Literature DB >> 21576085

Angiopoietin-2 TIEs up macrophages in tumor angiogenesis.

Michele De Palma1, Luigi Naldini.   

Abstract

Angiopoietin-2 (ANG2), a ligand of the TIE2 receptor, modulates endothelial cell biology and destabilizes blood vessels to facilitate angiogenesis. Recent reports have shown that ANG2 inhibition, for example, by monoclonal antibodies, peptibodies, or CovX-Bodies, may achieve substantial antiangiogenic and antitumor responses in a variety of mouse tumor models, including spontaneous MMTV-PyMT mammary and RIP1-Tag2 pancreatic islet adenocarcinomas. There is also evidence that targeting the ANG2/TIE2 signaling pathway may inhibit the functions of TIE2-expressing macrophages (TEM), a tumor-associated macrophage subset endowed with proangiogenic activity in mouse tumor models. The clinical opportunities afforded by simultaneously targeting the effects of ANG2 on tumor angiogenesis and the proangiogenic activity of TEMs are discussed. ©2011 AACR.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 21576085     DOI: 10.1158/1078-0432.CCR-10-0171

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  39 in total

1.  7th annual European Antibody Congress 2011: November 29-December 1, 2011, Geneva, Switzerland.

Authors:  Alexey A Lugovskoy; Janice M Reichert; Alain Beck
Journal:  MAbs       Date:  2012-03-01       Impact factor: 5.857

2.  Understanding and targeting resistance to anti-angiogenic therapies.

Authors:  Jeffrey M Clarke; Herbert I Hurwitz
Journal:  J Gastrointest Oncol       Date:  2013-09

3.  The angiopoietin-Tie2 signaling axis in the vascular leakage of systemic inflammation.

Authors:  Katelyn E Milam; Samir M Parikh
Journal:  Tissue Barriers       Date:  2015-04-03

Review 4.  Recent molecular discoveries in angiogenesis and antiangiogenic therapies in cancer.

Authors:  Jonathan Welti; Sonja Loges; Stefanie Dimmeler; Peter Carmeliet
Journal:  J Clin Invest       Date:  2013-08-01       Impact factor: 14.808

5.  Inflammatory monocyte mobilization decreases patient survival in pancreatic cancer: a role for targeting the CCL2/CCR2 axis.

Authors:  Dominic E Sanford; Brian A Belt; Roheena Z Panni; Allese Mayer; Anjali D Deshpande; Danielle Carpenter; Jonathan B Mitchem; Stacey M Plambeck-Suess; Lori A Worley; Brian D Goetz; Andrea Wang-Gillam; Timothy J Eberlein; David G Denardo; Simon Peter Goedegebuure; David C Linehan
Journal:  Clin Cancer Res       Date:  2013-05-07       Impact factor: 12.531

6.  Inhibition of endothelial/smooth muscle cell contact loss by the investigational angiopoietin-2 antibody MEDI3617.

Authors:  Nikolett Molnar; Dietmar W Siemann
Journal:  Microvasc Res       Date:  2012-02-23       Impact factor: 3.514

Review 7.  Targeting the Angiopoietin-2/Tie-2 axis in conjunction with VEGF signal interference.

Authors:  Nikolett M Biel; Dietmar W Siemann
Journal:  Cancer Lett       Date:  2014-10-12       Impact factor: 8.679

Review 8.  Molecular Pathways: Deciphering Mechanisms of Resistance to Macrophage-Targeted Therapies.

Authors:  Daniela F Quail; Johanna A Joyce
Journal:  Clin Cancer Res       Date:  2016-11-28       Impact factor: 12.531

9.  Isolation of Mouse and Human Tumor-Associated Macrophages.

Authors:  Luca Cassetta; Roy Noy; Agnieszka Swierczak; Gaël Sugano; Harriet Smith; Lisa Wiechmann; Jeffrey W Pollard
Journal:  Adv Exp Med Biol       Date:  2016       Impact factor: 2.622

10.  Hypoxia-Inducible Factor α Subunits Regulate Tie2-Expressing Macrophages That Influence Tumor Oxygen and Perfusion in Murine Breast Cancer.

Authors:  Kayla J Steinberger; Mary A Forget; Andrey A Bobko; Nicole E Mihalik; Marieta Gencheva; Julie M Roda; Sara L Cole; Xiaokui Mo; E Hannah Hoblitzell; Randall Evans; Amy C Gross; Leni Moldovan; Clay B Marsh; Valery V Khramstov; Timothy D Eubank
Journal:  J Immunol       Date:  2020-09-16       Impact factor: 5.422

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.